The discovery of nitric oxide (NO) as an intercellular messenger or neurotransmitter opened
a new era for identifying the important mechanisms underlying physiological and …

Up until a few years ago, pharmacologic treatment of erectile dysfunction (ED) was limited to
a few substances, most of which had to be injected directly into the corpora cavernosa. The …

The convincing clinical data on the use of the orally active phosphodiesterase inhibitors
sildenafil, vardenafil and tadalafil for the treatment of male erectile dysfunction have boosted …

The balance between contractant and relaxant factors controls the smooth muscle of the
corpus cavernosum and determines the functional state of the penis (detumescence and …

Despite the successes of Viagra TM, the quest for new and better therapy for erectile
dysfunction (ED) continues. In a recent survey of the first 220 patients placed on Viagra TM …

There has been a tremendous increase in demand for the treatment of erectile dysfunction in
the last 10 years. This has occurred partly because of a greater understanding and …

Thirty percent of males afflicted with erectile dysfunction (ED) do not respond to oral drugs,
another 15% reveal contraindications to currently available therapy, and a subset of patients …

Erectile dysfunction (ED) affects up to 50% of men between the ages of 40 and 70.
Treatment with PDE‐5 inhibitors is effective in the majority of men with ED. However, PDE‐5 …

Approximately 50% of men aged over 40 suffer from male erectile dysfunction. Treatment
options have widened since the launch of the phosphodiesterase type 5 (PDE5) inhibitor …

There is now a range of treatments for patients with erectile dysfunction (ED) beyond the
psychosexual counselling and surgical implants that were the only available management …